Stifel Nicolaus Reiterates Buy Rating for vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. (NASDAQ:VTVT)‘s stock had its “buy” rating reiterated by investment analysts at Stifel Nicolaus in a research report issued to clients and investors on Friday. They presently have a $12.00 target price on the biotechnology company’s stock. Stifel Nicolaus’ target price suggests a potential upside of 94.49% from the stock’s previous close.
VTVT has been the subject of several other research reports. Zacks Investment Research cut vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. Canaccord Genuity reissued a “buy” rating and issued a $15.00 price target on shares of vTv Therapeutics in a research note on Friday, August 4th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.10.
Shares of vTv Therapeutics (VTVT) traded up $0.08 on Friday, reaching $6.17. The company had a trading volume of 52,800 shares, compared to its average volume of 42,063. vTv Therapeutics has a 52-week low of $3.57 and a 52-week high of $8.09.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.02. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.19 million. analysts anticipate that vTv Therapeutics will post -1.21 earnings per share for the current year.
In related news, major shareholder Ronald O. Perelman bought 50,000 shares of vTv Therapeutics stock in a transaction dated Tuesday, August 15th. The stock was acquired at an average cost of $4.72 per share, with a total value of $236,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ronald O. Perelman bought 85,000 shares of vTv Therapeutics stock in a transaction dated Friday, August 11th. The shares were bought at an average cost of $4.13 per share, with a total value of $351,050.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 165,000 shares of company stock valued at $728,150. 0.80% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in vTv Therapeutics by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 1,305 shares in the last quarter. Renaissance Technologies LLC lifted its stake in vTv Therapeutics by 4.8% in the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 2,900 shares in the last quarter. State Street Corp lifted its stake in vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in vTv Therapeutics by 62.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after acquiring an additional 101,850 shares in the last quarter. 11.05% of the stock is owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.